Market Runner: Could Delcath Systems, Inc. Change Direction After Today’s Big Increase?

Market Runner: Could Delcath Systems, Inc. Change Direction After Today's Big Increase?

The stock of Delcath Systems, Inc. (NASDAQ:DCTH) is a huge mover today! The stock increased 7.81% or $0.15 on November 25, hitting $2.07. About 116,945 shares traded hands. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 64.71% since April 22, 2016 and is downtrending. It has underperformed by 70.12% the S&P500.
The move comes after 7 months positive chart setup for the $4.70 million company. It was reported on Nov, 25 by Barchart.com. We have $2.19 PT which if reached, will make NASDAQ:DCTH worth $282,000 more.

Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on March, 20.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 1.13, from 1.13 in 2016Q1. The ratio worsened, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Kcg Holding Inc accumulated 0% or 12,403 shares. Geode Mngmt Limited Co last reported 39,792 shares in the company. The United Kingdom-based Barclays Public Ltd has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Ladenburg Thalmann Fin Ser holds 0% or 1,456 shares in its portfolio. Royal National Bank & Trust Of Canada holds 2,563 shares or 0% of its portfolio. Moreover, Blackrock Institutional Com Na has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 531,871 shares. Deutsche Bank & Trust Ag has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Goldman Sachs Gp has 0% invested in the company for 15,211 shares. Vanguard has 0% invested in the company for 77,988 shares. Susquehanna International Group Inc Llp last reported 0% of its portfolio in the stock. Blackrock Fund Advisors last reported 4,024 shares in the company. Group One Trading Limited Partnership accumulated 5,123 shares or 0% of the stock. Creative Planning reported 307 shares or 0% of all its holdings. Retail Bank Of America De has 0% invested in the company for 4,604 shares. Wells Fargo And Mn holds 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH) for 157 shares.

More important recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Marketwatch.com which released: “Delcath Systems Inc.” on December 22, 2009, also Prnewswire.com published article titled: “Delcath Announces Third Quarter Financial Results”, Prnewswire.com published: “Delcath Issues Letter to Stockholders” on October 18, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) was released by: Equitiesfocus.com and their article: “Delcath Systems, Inc. (NASDAQ:DCTH) Quarterly EPS From Continuing Operations …” with publication date: November 25, 2016.

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment